Eliem Therapeutics Retained Earnings (Accumulated Deficit) 2021-2024 | CLYM
Eliem Therapeutics retained earnings (accumulated deficit) from 2021 to 2024. Retained earnings (accumulated deficit) can be defined as profits reinvested in the corporation after dividends have been paid out.
Eliem Therapeutics Annual Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2023 |
$-156 |
| 2022 |
$-121 |
| 2021 |
$-76 |
| 2020 |
$-28 |
Eliem Therapeutics Quarterly Retained Earnings (Accumulated Deficit)
(Millions of US $) |
| 2024-06-30 |
$-213 |
| 2024-03-31 |
$-158 |
| 2023-12-31 |
$-156 |
| 2023-09-30 |
$-152 |
| 2023-06-30 |
$-148 |
| 2023-03-31 |
$-143 |
| 2022-12-31 |
$-121 |
| 2022-09-30 |
$-113 |
| 2022-06-30 |
$-103 |
| 2022-03-31 |
$-89 |
| 2021-12-31 |
$-76 |
| 2021-09-30 |
$-65 |
| 2021-06-30 |
$-55 |
| 2021-03-31 |
|
| 2020-12-31 |
|
| 2020-09-30 |
|
| 2020-06-30 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
MED-DRUGS |
$0.342B |
$0.000B |
|
Eliem Therapeutics Inc. is a clinical-stage biotechnology company. It focused on developing novel therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Eliem Therapeutics Inc. is based in SEATTLE, United Kingdom.
|
